Angiogenesis pp 307-310 | Cite as
Inhibition of VEGF Signal Transduction
Identification of ZD4190
Chapter
Abstract
There is a significant unmet need for cytostatic (i.e. non-cytotoxic) therapy to stabilise or slow the progression of solid tumour disease, particularly in non-hormone dependent cancers. Anti-angiogenics are one approach which might satisfy this need. Experience from the anti-hormonal cytostatics suggests that chronic dosing will be required and hence oral delivery of drug is preferable. Side effects will also need to be compatible with the clinical benefit.
Keywords
Tumour Xenograft Model Chronic Dose VEGF Signalling Human Tumour Xenograft Model Femur Growth Plate
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Preview
Unable to display preview. Download preview PDF.
References
- Curwen, J.O. and Ogilvie, D.J., 1997, Production of the angiogenic factors VEGF and bFGF at tumour sites may also confer an acute haemodynamic advantage to the tumour. Br. J. Cancer 75: P89.Google Scholar
- Folkman J., 1995, Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Medicine, 1: 27–31.PubMedCrossRefGoogle Scholar
- Kim, K.L., Li B., Winer J., Armanini M., Gillett N., Phillips, H.S., and Ferrara, N., 1993, Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 362: 841–844.PubMedCrossRefGoogle Scholar
- Ryan, A.M., Eppler, D.B., Hagler, K.E., Bruner, R.H., Thomford, P.J., Hall, R.L., Shopp, G.M., and O’Niell, C.A., 1999, Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanised monoclonal antibody. Tox. Path., 27: 78–86.CrossRefGoogle Scholar
- Senger, D.R., Van De Water L., Brown, L.F., Nagy, J.A., Yeo, K.T., Yeo, T.K., Berse B., Jackman, R.W., Dvorak, A.M., and Dvorak, H.F., 1993, Vascular permeability factor (VPF,VEGF) in tumor biology. Cancer and Metastasis Reviews 12: 303–324.PubMedCrossRefGoogle Scholar
- Wedge, S.R., Waterton, J.C., Tessier, J.J., Checkley D., Dukes M., Kendrew, J. and Curry, B., 1999, Effect of the VEGF receptor tyrosine kinase inhibitor ZD4190 on vascular endothelial permeability. Proc. Amer. Assoc. Cancer Res. 40: 2741.Google Scholar
Copyright information
© Springer Science+Business Media New York 2000